Kestra Medical Technologies (NASDAQ:KMTS) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Kestra Medical Technologies (NASDAQ:KMTS) from a hold rating to a sell rating in a research report report published on Saturday.

A number of other equities analysts have also issued reports on the company. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group lowered their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $27.83.

Kestra Medical Technologies Stock Down 4.8%

KMTS stock opened at $23.24 on Friday. The firm’s 50-day moving average is $22.31 and its two-hundred day moving average is $22.66. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -9.60 and a beta of 0.47. Kestra Medical Technologies has a 52 week low of $14.10 and a 52 week high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million during the quarter. On average, analysts forecast that Kestra Medical Technologies will post -2.3 earnings per share for the current fiscal year.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total value of $312,150.00. Following the transaction, the insider owned 395,467 shares in the company, valued at approximately $8,229,668.27. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Several large investors have recently modified their holdings of the stock. Seven Grand Managers LLC acquired a new position in shares of Kestra Medical Technologies in the fourth quarter worth about $2,652,000. Eventide Asset Management LLC increased its position in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $9,282,000. UBS Group AG raised its holdings in shares of Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after acquiring an additional 69,908 shares during the period. Finally, Next Century Growth Investors LLC lifted its position in shares of Kestra Medical Technologies by 154.5% in the 4th quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock valued at $12,354,000 after acquiring an additional 282,832 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.